A Multicenter, Randomized, Double-blind, Placebo-controlled, Flexible-dose Study to Assess the Efficacy, Safety, and Tolerability of ITI 1284 in Patients With Psychosis Associated With Alzheimer's Disease
Latest Information Update: 04 Sep 2026
At a glance
- Drugs Lumateperone (Primary)
- Indications Alzheimer's disease; Psychiatric disorders
- Focus Therapeutic Use
- Sponsors Intra-Cellular Therapies
Most Recent Events
- 06 Jul 2026 Planned End Date changed from 1 Oct 2027 to 29 Dec 2028.
- 06 Jul 2026 Planned primary completion date changed from 1 Sep 2027 to 30 Sep 2028.
- 09 Jun 2026 This trial has been discontinued in Poland (Feasibility (recruitment issues, etc)), according to Clinical Trials Information System.